Jane Jialu Xu

Jane Jialu Xu

Auto-generated profile, based on publicly available information

Jane Jialu Xu

Columbia University Medical Center, New York City, New York, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2016 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
BSBoris Shor
Boris Shor
JKJennifer Kahler
Jennifer Kahler
MDMaureen Dougher
Maureen Dougher
JXJane Xu
Jane Xu
MMMichelle Mack
Michelle Mack
PSPuja Sapra
Puja Sapra
Purpose: Targeted treatment of solid or liquid tumors with antibody-drug conjugates (ADCs) can lead to pronounced clinical benefit. The aim of the study is to investigate the most promising combination regimens of auristatin-based conjugates in preclinical models of cancer. Experimental Design: An auristatin-based anti-5T4 antibody conjugate (5T4-ADC) and auristatin payloads were combined with the dual PI3K/mTOR catalytic site inhibitor PF-05212384 (PF-384) or taxanes in a panel of tumor cell lines. Drug interactions in vitro were evaluated using cell viability assays, apoptosis induction, immunofluorescence, mitotic index, and immunoblotting. Breast cancer cells treated with auristatin analog or 5T4-ADC were profiled by total- and phospho-proteomics. Anti-tumor efficacy of selected combinations was evaluated in 5T4-positive human breast or lung tumor xenografts in vivo. Results: In vitro, auristatin-based agents displayed strong synergistic or additive activity when combined with PF-384 or taxanes respectively. Further, treatment of 5T4-ADC plus PF-384 resulted in stronger induction of apoptosis and cell-line-specific attenuation of pAKT and pGSK. Interestingly, proteomic analysis revealed unique effects of auristatins on multiple components of mRNA translation. Addition of PF-384 further amplified effects of 5T4-ADC on translational components, providing a potential mechanism of synergy between these drugs. In human tumor xenografts, dual targeting with 5T4-ADC/PF-384 or 5T4-ADC/paclitaxel produced substantially greater antitumor effects with longer average survival as compared to monotherapy treatments. Conclusions: Our results provide a biologic rationale for combining 5T4-ADC with either PI3K/mTOR pathway inhibitors or taxanes and suggest that mechanisms underlying the synergy may be attributed to cellular effects of the auristatin payload.

21 October 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
JXJane Jialu Xu
Jane Jialu Xu
ACAlistair M. Chalk
Alistair M. Chalk
MWMeaghan Wall
Meaghan Wall
WLWallace Y. Langdon
Wallace Y. Langdon
MSMonique F. Smeets
Monique F. Smeets
CWCarl R. Walkley
Carl R. Walkley

4 April 2024 in Experimental Hematology
Verified
Journal Article
Closed access
JXJane Jialu Xu
Jane Jialu Xu
AVAaron D. Viny
Aaron D. Viny

18 May 2026 in Blood
Verified
Journal Article
Open access
VSVarun S Sudunagunta
Varun S Sudunagunta
ESEdna M Stewart
Edna M Stewart
YCYi Chen
Yi Chen
HYHongxia Yan
Hongxia Yan
SFSebastian Fernando
Sebastian Fernando
AVAaron D Viny
Aaron D Viny
The transcription factor GATA1 has pleiotropic hematopoietic functions, particularly in erythroid and megakaryocytic ontogeny. While mechanistic investigations have uncovered many facets of GATA1 biology, how GATA1 co-regulates divergent cell fates remains incompletely characterized. We previously described that loss of Stag2, a member of the cohesin complex and a recurrent mutational target in myelodysplastic syndrome (MDS) and myeloid leukemia of Down Syndrome, results in altered chromatin accessibility, transcription factor function, and cell differentiation. Hence, we hypothesized that chromatin accessibility determines GATA1 cistrome specificity and lineage fate decisions. To understand the connection between chromatin accessibility and GATA1, we comprehensively studied erythropoiesis in Stag2∆ mice. Defects in Stag2-deficient hematopoiesis included reduced numbers of erythroid progenitors (EryPs), impaired terminal erythroid differentiation, increased number of MkPs, and increased megakaryocytes. RNA- and ATAC-sequencing of EryPs revealed altered patterns of Gata1 target gene expression with altered accessibility in conjunction with loss of expression of erythroid targets and gain of megakaryocyte targets. Despite unchanged Gata1 expression, Gata1 occupancy was reprogrammed from erythroid to megakaryocyte targets with Fli1 motifs enriched at Stag2∆ Gata1 binding sites. Functionally, we observed that Stag2-deficient EryPs have diminished erythroid output and augmented megakaryocyte output in orthogonal differentiation assays, which was partially reversed with Fli1 knockdown. Human models and primary MDS patients recapitulated the essential phenotypic and molecular features of our in vivo murine MDS model. Collectively, this study establishes chromatin accessibility as a determinant of transcription factor binding specificity, revealing an accessibility-driven Gata1 retargeting mechanism underlying MDS dyserythropoiesis.

3 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
JXJane J. Xu
Jane J. Xu
VSViviana Scoca
Viviana Scoca
YCYi Chen
Yi Chen
YZYingqian A. Zhan
Yingqian A. Zhan
AFAlexander Fisher
Alexander Fisher
AVAaron D. Viny
Aaron D. Viny
Transcription factors (TFs) influencing cell fate can be dysregulated in cancer. FLI1 is crucial for hematopoietic stem/progenitor cell (HSPC) function, with STAG2 regulating FLI1 target accessibility. STAG2 depletion enhances HSPC self-renewal, but its role in leukemic transformation is unclear. We uncovered that STAG2 loss maintains FLI1 target accessibility in murine HSPCs and enhances FLI1 binding in NPM1c leukemia. In our Stag2/Npm1c/+ murine model, myeloid-biased HSPCs with increased FLI1 accessibility are reservoirs for transformation, leading to a fully penetrant leukemia. STAG2 deleted NPM1c cell lines exhibit increased chromatin accessibility and chromatin-looping of key stem and leukemia genes including FLI1-target genes CD34 and MEN1. Similarly, enrichment for a CD34+ immunophenotype was observed in co-mutant leukemia patients. STAG2 deficient cells show increased chromatin-bound MENIN and increased sensitivity to MENIN inhibition. Our findings demonstrate that altered chromatin architecture can co-opt oncogenic TF signaling, such as FLI1, as a hallmark of leukemogenesis. Key Findings: Loss of STAG2 results in aberrant increased accessibility at FLI1 targets in mouse and human hematopoietic stem and progenitor cells Increased accessibility results in an increased fraction of chromatin-bound FLI1, which overlap with NPM1c targets in STAG2 NPM1c AML cells Stag2 Npm1c co-mutation leads to dysplastic murine AML phenotype arising from myeloid biased progenitors that exhibit increased Fli1 target accessibility In addition to higher chromatin-bound FLI1, co-mutant cells have higher chromatin-bound MENIN, including at the HOXA cluster, rendering cells highly sensitive to MENIN inhibition. Statement of Significance: Here, we identify enhanced FLI1 chromatin accessibility as a driver of stemness and leukemic transformation in STAG2 mutant leukemia. Through comprehensive in vivo and in vitro modeling, we demonstrate that altered chromatin architecture can co-opt oncogenic TF activity, like FLI1, to drive divergent leukemia development and therapeutic response.

21 June 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JXJane Jialu Xu
Jane Jialu Xu
ACAlistair M. Chalk
Alistair M. Chalk
MWMeaghan Wall
Meaghan Wall
WLWallace Y. Langdon
Wallace Y. Langdon
MSMonique F. Smeets
Monique F. Smeets
CWCarl R. Walkley
Carl R. Walkley
Recurrent mutations in two pathways - the RNA spliceosome (eg. SRSF2, SF3B1, U2AF1 ) and epigenetic regulators (eg. DNMT3, TET2 ) – contribute to the development of myelodysplastic syndrome (MDS) and related myeloid neoplasms. In chronic myelomonocytic leukemia (CMML), SRSF2 mutations occur in ∼50% of patients and TET2 mutations in ∼60%, representing two of the most frequent mutations in these cancers. Clonal analysis has indicated that either mutation can arise as the founder lesion, however, our understanding of the basis for the co-operativity of these mutations in the evolution of CMML is limited. Based on human cancer genetics we crossed an inducible Srsf2 P95H/+ mutant model with Tet2 fl/fl mice to mutate both concomitantly (or individually) in hematopoietic stem cells. At 20-24 weeks post gene mutation, we observed subtle differences in the Srsf2 / Tet2 mutants compared to either single mutant. Under conditions of native hematopoiesis with aging, we see a distinct myeloid bias and monocytosis in the Srsf2 / Tet2 mutants. A subset of the compound Srsf2 / Tet2 mutants display an increased granulocytic and distinctive monocytic proliferation (myelo-monocytic hyperplasia), with increased immature promonocytes and monoblasts (∼10-15% total nucleated cells), and evidence of binucleate promonocytes. Exome analysis of progressed disease demonstrates mutations in genes and pathways similar to those reported in human CMML. Upon transplantation, recipients developed leukocytosis, monocytosis and splenomegaly. This demonstrates we can reproduce Srsf2/Tet2 co-operativity in vivo , yielding a disease with core characteristics of CMML, unlike single Srsf2 or Tet2 mutation. This model represents a significant step toward building high fidelity and genetically tractable models of CMML. Key points: Srsf2 P95H/+ co-operates with Tet2 -/- to initiate CMML in a murine model Srsf2 P95H and Tet2 null mutations synergize in the development of monocytosis